Vyvgart Hytrulo (Efgartigimod Alfa + Hyaluronidase)
First FDA-approved FcRn inhibitor for CIDP — a 30-second weekly injection at home
Route
Subcutaneous injection
Frequency
Once weekly
Setting
Home self-administration (after training)
FDA Status
FDA-approved June 2024 for adults with CIDP
Educational use only. This page explains how Vyvgart Hytrulo works based on clinical guidelines and trial data. It cannot replace your neurologist. All treatment decisions must be made with your medical team.
How Vyvgart Hytrulo Works
Vyvgart Hytrulo works through a fundamentally different mechanism than IVIG or SCIg. Rather than supplying immunoglobulin, it uses FcRn (neonatal Fc receptor) blockade to accelerate the breakdown of all IgG antibodies in the blood — including the specific pathogenic antibodies that attack peripheral nerve myelin in CIDP.
- •FcRn is a recycling receptor that normally rescues IgG antibodies from degradation, extending their half-life from days to ~21 days
- •Efgartigimod alfa binds FcRn and blocks this recycling, causing all circulating IgG to be degraded at a much faster rate
- •This reduction in total IgG includes the pathogenic anti-myelin antibodies driving nerve damage in CIDP
- •Hyaluronidase (the "-qvfc" component) temporarily breaks down hyaluronic acid in subcutaneous tissue, allowing rapid absorption of the large molecule
- •Unlike IVIG, Vyvgart Hytrulo does not modulate the immune system — it depletes existing antibodies; this means it also reduces protective IgG (see side effects)
- •The mechanism is particularly useful in CIDP cases where antibodies are clearly driving the disease (e.g., anti-NF155 or anti-CNTN1 positive)
Clinical Evidence
In the Phase 3 ADHERE trial (published NEJM 2023), Vyvgart Hytrulo demonstrated significant and durable improvement in CIDP symptoms. The trial enrolled CIDP patients who were on stable IVIG or SCIg and were at risk of relapse, confirming efficacy in a well-characterized population.
| Metric | Value | Source |
|---|---|---|
| Patients with significant improvement | 69% | ADHERE trial, NEJM 2023 |
| Reduction in relapse risk vs. placebo | 61% | ADHERE trial, NEJM 2023 |
| Median time to first response | ~4 weeks | ADHERE trial |
| FDA approval date | June 2024 | FDA press release |
| Evidence level | Phase 3 RCT | ADHERE trial |
| Injection time | 30–90 seconds | argenx prescribing information |
The ADHERE trial used a run-in period where all patients received standard IVIG/SCIg to confirm active disease, then were randomized. This design ensures the results reflect genuine disease activity rather than natural remission.
Vyvgart Hytrulo does not have the wearing-off pattern seen with IVIG because its mechanism (FcRn blockade) works continuously rather than through periodic large doses. Weekly injections maintain steady-state FcRn saturation.
Side Effects
Common
- •Injection site reactions: redness, bruising, swelling, or itching at the injection site (usually mild and transient)
- •Upper respiratory tract infections (common cold symptoms)
- •Urinary tract infections
- •Fatigue
- •Headache (less common than with IVIG)
Serious (less common)
- •Increased infection risk: Vyvgart Hytrulo reduces ALL circulating IgG antibodies — including those protecting against bacterial and viral infections. Patients with pre-existing low IgG or frequent infections may be at higher risk.
- •Hypersensitivity reactions: allergic reactions including anaphylaxis (rare); monitor after first injection
- •Infusion-related reactions during the subcutaneous injection (uncommon)
The most important safety consideration for Vyvgart Hytrulo is the reduction in total IgG, including protective antibodies. Your neurologist should monitor IgG levels during treatment. If you develop frequent or severe infections, inform your neurologist — a dose reduction, treatment break, or switch to a different therapy may be warranted. Patients should be up to date on vaccines before starting treatment.
Pros & Cons
Advantages
- ✓Weekly 30-second subcutaneous injection — no infusion center visits
- ✓Home self-administration after initial training
- ✓No wearing-off pattern (continuous FcRn blockade)
- ✓Strong Phase 3 evidence (ADHERE trial, NEJM 2023)
- ✓Useful when IVIG has failed or is not tolerated
- ✓Different mechanism opens a new treatment option for refractory cases
Drawbacks
- –Reduces ALL IgG — including protective antibodies (infection risk)
- –Newest agent: less long-term safety data than IVIG or steroids
- –Insurers often require documented IVIG failure or intolerance first (step therapy)
- –Expensive; patient assistance program available but access varies
- –Requires weekly injection discipline
- –Not suitable for patients with very low baseline IgG
Insurance & Access
- →Prior authorization required; most insurers currently require documented IVIG failure or intolerance before approving Vyvgart Hytrulo
- →argenx (manufacturer) offers the "TOGETHER" patient support program with copay assistance and prior authorization support: 1-833-VYVGART
- →Medicare coverage is evolving; as of 2024, Part B covers self-administered injectables in limited circumstances — check with your insurer
- →If denied based on step therapy, document any IVIG side effects (headache, fatigue, wearing off) and ask your neurologist to submit a peer-to-peer review
- →The strong Phase 3 ADHERE trial data (NEJM 2023) is useful evidence in appeals
Have a question about Vyvgart Hytrulo?
Ask the AI assistant for more detail — dosing questions, wearing-off, insurance appeals, how Vyvgart Hytrulo compares to other options, and more.
Ask the AI →Other CIDP Treatments
IVIG
The most widely used first-line treatment for CIDP, with Level A evidence
SCIg
Weekly home injections that eliminate infusion center visits and the wearing-off effect
Plasma Exchange
A fast-acting procedure that physically removes harmful antibodies from the blood
Corticosteroids
Oral or IV steroids that broadly suppress immune activity — effective but with long-term trade-offs
Sources
- van Schaik IN, et al. Efgartigimod alfa and hyaluronidase-qvfc in CIDP (ADHERE). N Engl J Med. 2023;388(25):2335–2347.
- FDA. Approval of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) for CIDP. June 2024.
- argenx. Vyvgart Hytrulo Prescribing Information. 2024.